Spotlight on topical pimecrolimus in atopic dermatitis

American Journal of Clinical Dermatology

Volumn 3, Issue 6, 2002, Pages 435-438

  Wellington, Keri ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PIMECROLIMUS;

ADOLESCENT; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ECZEMA; HUMAN; INFANT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN ATROPHY; SYMPTOMATOLOGY;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, ATOPIC; HUMANS; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 0036342706     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203060-00006     Document Type: Review

References (23)

1. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
2. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils
3. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner
4. SDZ ASM 981 potently inhibits the induction of coreceptors involved in the accessory cell-dependent activation of inflammation-mediating T cells
5. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study
6. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge
7. First experience of topical SDZ ASM 981 in children with atopic dermatitis
8. Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis
9. Pimecrolimus (Elidel, SDZ ASM 981 cream 1%) blood levels are consistently low in children with extensive atopic eczema
10. Low blood concentrations of pimecrolimus (Elidel, SDZ ASM 981) after topical treatment of adults with atopic dermatitis
11. Oral SDZ ASM981: Pharmacokinetic profile in humans; summary in 2 parts (Part A)
12. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
13. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis
14. Pimecrolimus (SDZ ASM 981) cream reduces the need for corticosteroids in the long-term management of atopic dermatitis in adults
15. Pimecrolimus (Elidel, SDZ ASM 981) cream 1% is effective and safe in infants aged 3-23 months with atopic dermatitis
16. Pimecrolimus (Elidel, SDZ ASM 981) cream 1%: A new approach to long-term management of atopic dermatitis in infants 3 to 23 months of age
17. SDZ ASM 981 cream 1% is effective and safe in children and adolescents with atopic dermatitis
18. Pimecrolimus (Elidel, SDZ ASM 981) cream 1% is safe in the long-term management of atopic dermatitis
19. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on quality of life in the treatment of pediatric atopic dermatitis: Results of two 6-week randomized double-blind vehicle-controlled clinical trials in the US
20. SDZ ASM 981 cream 1%: A new approach to long-term management of atopic dermatitis
21. Pimecrolimus (SDZ ASM 981) cream reduces the number of flares and the need for topical corticosteroids in children with atopic dermatitis: A 12-month, double-blind, controlled study